Increased Bcl-2/Bax ratios have also been correlated to a more aggressive behaviour of B-CLL, including progressive disease, refractoriness to chemotherapy, and shorter survival (Aguilar-Santelises et al, 1996, Pepper et al, 1998). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.